Ignite Creation Date:
2024-05-05 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00142350
Status:
COMPLETED
Last Update Posted:
2016-09-12
First Post:
2005-09-01
Brief Title:
A Study of 5-FUci Versus CPT-11 Plus CDDP Versus S-1 Alone in Advanced Gastric Cancer
Sponsor:
Japan Clinical Oncology Group
Organization:
Japan Clinical Oncology Group
Study Overview
Official Title:
Randomized Phase III Study of 5-FU Continuous Infusion 5-FUci Versus CPT-11 Plus CDDP CP Versus S-1 Alone S-1 in Advanced Gastric Cancer JCOG9912
Status:
COMPLETED
Status Verified Date:
2016-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To investigate the superiority of a combination of irinotecan and cisplatin and the non-inferiority of S-1 compared to continuous infusion of 5-FU in advanced gastric cancer
Detailed Description:
From the results of our previous phase III study JCOG9205 continuous infusion of 5-fluorouracil has remained to be a control arm of this study This study investigates the superiority of a combination of irinotecan plus cisplatin and non-inferiority of S-1 a oral fluoropyrimidine compared to continuous infusion of 5-fluorouracil at the point of overall survival and the planned number of enrolled patients is 690 230arm
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| C000000062 | None | None | None |